Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NYMALIZE vs CALAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
NMDA receptor antagonist; acts as a neuroprotective agent by reducing excitotoxicity and modulating calcium influx. Also binds to sigma-1 receptors, possibly contributing to neuroprotection.
Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.
FDA-approved for the treatment of agitation associated with schizophrenia and bipolar I disorder (maintenance therapy). Off-label: treatment of agitation in Alzheimer's disease and other dementias, major depressive disorder (adjunct), obsessive-compulsive disorder, and other psychiatric conditions.
Angina pectoris (chronic stable, vasospastic, unstable),Essential hypertension,Supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter, PSVT)
10 mg (5 m L) intravenously over 5-15 minutes, may repeat after 15 minutes if needed; followed by continuous infusion of 0.9-2.0 mg/hour (5-10 m L/hour).
Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.
Terminal elimination half-life is approximately 8–9 hours (range 5–12 hours) in patients with subarachnoid hemorrhage. In elderly or hepatically impaired patients, half-life may be prolonged. Clinically, steady-state is achieved after 3–5 days of oral dosing.
Terminal elimination half-life is 3-7 hours for immediate-release; can be prolonged to 12-16 hours with sustained-release due to slow absorption; increased in hepatic impairment.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6; forms active metabolites (e.g., dextrorphan and 3-methoxymorphinan).
Extensively metabolized in the liver via CYP3A4, CYP1A2, and CYP2C8 isoenzymes; undergoes N-dealkylation and O-demethylation; first-pass metabolism results in low bioavailability (20-35%).
Nymalize (nimodipine) is primarily eliminated via hepatic metabolism. Approximately 50% of the dose is excreted in urine as metabolites and <1% as unchanged drug. Fecal excretion accounts for ~20% of metabolites. Less than 1% is excreted unchanged in bile. Renal clearance is negligible for parent compound.
Approximately 70% renal (3-4% unchanged, remainder as metabolites) and 25% biliary/fecal.
Nimodipine is 97–99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 90% bound to plasma proteins, primarily albumin.
Volume of distribution is approximately 0.8–1.6 L/kg. This large Vd indicates extensive tissue distribution, including penetration into the brain (cerebrospinal fluid concentrations are about 10% of plasma levels).
Vd 4-5 L/kg; indicates extensive tissue distribution beyond plasma volume.
Oral bioavailability is approximately 13% (range 3–30%) due to extensive first-pass hepatic metabolism. Intravenous administration yields 100% bioavailability.
Oral bioavailability is 20-35% due to extensive first-pass hepatic metabolism; IV bioavailability is 100%.
No dose adjustment required for renal impairment; not removed by hemodialysis.
Cr Cl <30 m L/min: reduce dose by 50% and monitor carefully.
Child-Pugh B or C: reduce dose by 50%; consider alternative therapy in severe hepatic impairment.
Child-Pugh A: 50% of normal dose; Child-Pugh B: 25% of normal dose; Child-Pugh C: contraindicated or use with extreme caution.
Not approved for pediatric use; safety and efficacy not established.
Oral: 4-8 mg/kg/day in 3 divided doses; IV: 0.1-0.3 mg/kg over 2 minutes, max 5 mg.
No specific dose adjustment; monitor for hypotension due to age-related decreased baroreceptor sensitivity.
Start at lowest dose (e.g., 40 mg 3 times daily) and titrate slowly; monitor for hypotension and bradycardia.
No FDA black box warning.
Contains verapamil hydrochloride. Risk of serious adverse effects including hypotension, bradycardia, AV block, and cardiac arrest. Must not be administered to patients with severe left ventricular dysfunction, cardiogenic shock, or sick sinus syndrome (unless paced).
Risk of abuse, dependence, and withdrawal; may cause cognitive and motor impairment; contraindicated in combination with other NMDA antagonists; use caution in patients with respiratory depression, severe hepatic impairment, or recent myocardial infarction.
May cause hypotension, bradycardia, AV block, and exacerbation of heart failure. Avoid in patients with pre-existing conduction abnormalities. Use caution with beta-blockers, digoxin, and CYP3A4 inhibitors. Abrupt withdrawal may exacerbate angina. May increase lithium and carbamazepine levels.
Hypersensitivity to the drug; concomitant use with other NMDA antagonists (e.g., ketamine, methoxetamine); monotherapy for schizophrenia; severe hepatic impairment (Child-Pugh class C).
Severe left ventricular dysfunction, cardiogenic shock, sick sinus syndrome (without pacemaker), second- or third-degree AV block (without pacemaker), atrial flutter/fibrillation with accessory bypass tract (e.g., WPW syndrome), concurrent use of IV beta-blockers.
Grapefruit juice increases nimodipine plasma concentrations by inhibiting CYP3A4 metabolism, potentially leading to toxicity. Avoid grapefruit products entirely. Alcohol may exacerbate hypotension and dizziness. No other significant food interactions.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing verapamil levels and risk of toxicity. Limit alcohol intake as it may enhance hypotensive effects. High-fat meals may delay absorption but not extent; take consistently with regard to meals.
First trimester: Cases of metabolic acidosis and respiratory depression in the neonate have been reported with intravenous nimodipine during pregnancy; however, oral nimodipine (NYMALIZE) lacks adequate studies. Second and third trimesters: Potential for maternal hypotension and reduced uteroplacental perfusion. Overall, nimodipine is an FDA Pregnancy Category C drug. Use only if potential benefit justifies risk to the fetus.
First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal bradycardia, hypotension, and impaired placental perfusion; avoid use for pregnancy-induced hypertension due to risk of fetal hypoxia.
Nimodipine is excreted in human milk. The M/P ratio is not established. Due to potential for serious adverse reactions in nursing infants, discontinue breast-feeding or discontinue drug, taking into account the importance of the drug to the mother.
Verapamil (CALAN) is excreted into breast milk; M/P ratio approximately 0.6. The relative infant dose is low (estimated <5% of maternal weight-adjusted dose). No adverse effects reported in breastfed infants. Caution in preterm infants or those with renal impairment.
No specific pharmacokinetic studies in pregnancy. Due to increased plasma volume and clearance, higher doses may be needed to achieve therapeutic levels; however, no established dosing guidelines. Use lowest effective dose and monitor clinical response and blood pressure.
Pregnancy may increase clearance of verapamil; monitoring of therapeutic effect advised. Dose may need adjustment based on clinical response. Avoid use in pregnancy-induced hypertension.
Nymalize (nimodipine) is a calcium channel blocker used specifically to prevent vasospasm following subarachnoid hemorrhage (SAH). It must be administered via nasogastric tube if the patient has impaired swallowing or is intubated. Monitor blood pressure closely due to risk of hypotension. Enteral administration is preferred over IV; if IV is used, avoid PVC tubing as nimodipine adsorbs to PVC. Do not administer with grapefruit juice.
Calan (verapamil) is a class IV antiarrhythmic and calcium channel blocker. Use caution in patients with hepatic impairment due to reduced clearance; dose adjustment may be needed. Avoid in patients with pre-existing bradycardia, second- or third-degree AV block, or sick sinus syndrome unless a pacemaker is present. May increase digoxin levels; monitor digoxin concentrations. Use with caution in patients with hypertrophic cardiomyopathy. For IV administration, have calcium gluconate available to reverse hypotension or bradycardia. Not recommended for use in acute myocardial infarction or cardiogenic shock.
Take this medication exactly as prescribed, even if you feel well.,If you cannot swallow the capsule, the liquid can be extracted using a needle and taken orally or via feeding tube.,Do not consume grapefruit or grapefruit juice while taking this medication.,Avoid alcohol as it may increase dizziness or hypotension.,Sit up slowly from lying or sitting position to prevent dizziness from low blood pressure.,Store capsules at room temperature away from light and moisture.
Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.,Avoid grapefruit juice as it can increase verapamil levels and risk of side effects.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid alcohol as it may worsen side effects like dizziness or low blood pressure.,Report symptoms of bradycardia (slow heart rate), palpitations, shortness of breath, or swelling of ankles/feet.,This medication may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Do not consume grapefruit or its juice during treatment.,Keep a regular medication schedule and do not change brands without doctor approval.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NYMALIZE vs CALAN, answered by our medical review team.
NYMALIZE is a Calcium Channel Blocker that works by NMDA receptor antagonist; acts as a neuroprotective agent by reducing excitotoxicity and modulating calcium influx. Also binds to sigma-1 receptors, possibly contributing to neuroprotection.. CALAN is a Calcium Channel Blocker that works by Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NYMALIZE and CALAN depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NYMALIZE is: 10 mg (5 m L) intravenously over 5-15 minutes, may repeat after 15 minutes if needed; followed by continuous infusion of 0.9-2.0 mg/hour (5-10 m L/hour).. The standard adult dose of CALAN is: Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NYMALIZE and CALAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NYMALIZE is classified as Category C. First trimester: Cases of metabolic acidosis and respiratory depression in the neonate have been reported with intravenous nimodipine during pregnancy; however, oral nimodipine (NY. CALAN is classified as Category C. First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.